Phase I-II to Evaluate Efficacy/Safety of Sorafenib+Gemcitabine+Radiotherapy in Locally Advanced Pancreatic Carcinoma
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
Phase I: Safety profile and to determine maximum tolerated dose (MTD) / Recommended Dose (DR)
of Sorafenib in combination with Gemcitabine and Radiotherapy
Phase II: Activity profile evaluating Progression-free rates (PFR) at 6 months, Response
rate, Overall survival, Toxicity profile
Phase:
Phase 1
Details
Lead Sponsor:
Grupo Espanol Multidisciplinario del Cancer Digestivo